微信小陈
微信小章| 产品名称： | BC-2 |
|---|---|
| 商品货号： | TS212601 |
| Organism： | Homo sapiens, human |
| Tissue： | pleural effusion |
| Cell Type： | B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 Cells contain EBV and KSHV (HHV-8) viral genomes
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | lymphoma |
| Age： | 31 years adult |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | Transfection host The BC-2 cell line allows in vitro culture of KSHV viral genomes. It is also a practical source of KSHV DNA to be used as a positive control for screening tests. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | BC-2 is a lymphoma cell line originated in 1992 by Ethel Cesarman and Giorgio Inghirami in the laboratory of Daniel M. Knowles. The cells were derived from a pleural cavity based lymphomatous effusion. |
| Antigen Expression： | CD45 +; EMA + (epithelial membrane antigen) |
| Comments： | The cells contain two viral genomes: Epstein-Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV, provisionally designed HHV-8). KSHV is a recently identified and largely uncharacterized virus. xa0 |
| Complete Growth Medium： | RPMI 1640 medium, 80%; fetal bovine serum, 20%
|
| Subculturing： | Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 4 to 5 x 105viable cells/mL. Maintain cultures at cell concentrations between 3 x 105 and 2 x 106 viable cells/mL.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Complete growth medium, 95%; DMSO, 5%. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Population Doubling Time： | 48 to 72 hrs |
| Name of Depositor： | Cornell Res. Fndn., Inc. |
| U.S. Patent Number： | |
| References： | Moore PS, et al. Primary characterization of a herpesvirus agent associated with Kaposis sarcoma. J. Virol. 70: 549-558, 1996. PubMed: 8523568 Cesarman E, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposis sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86: 2708-2714, 1995. PubMed: 7670109 Chadburn A, et al. CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72: 3078-3090, 1993. PubMed: 8221575 Cesarman E, et al. Kaposis sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N. Engl. J. Med. 332: 1186-1191, 1995. PubMed: 7700311 Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |